Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer

Hereditary Cancer in Clinical Practice

Volumn 13, Issue 1, 2015, Pages

  Timoteo, Ana Rafaela de Souza ^a   Albuquerque, Betina Menezes ^b   Moura, Patricia Cristina Pascoto ^b   Ramos, Carlos Cesar de Oliveira ^b   Agnez Lima, Lucymara Fassarela ^a   Walsh, Tom ^c   King, Mary Claire ^c   Lajus, Tirzah Braz Petta ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b Hospital Liga Norte Riograndense Contra o Câncer   (Brazil)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

BRCA2 mutation; Large genomic deletion; Male Breast Cancer (MBC); Next generation sequencing

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NUCLEOTIDE; PAMIDRONIC ACID; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; BONE SCINTISCANNING; BREAST BIOPSY; BREAST CARCINOMA; BREAST DISEASE; BREAST NODULE; CANCER RADIOTHERAPY; CASE REPORT; EXOME; EXON; FAMILY HISTORY; GENE DELETION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GENOMICS; GERMLINE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MALE BREAST CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; PEDIGREE; PHYSICAL EXAMINATION; RADICAL MASTECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 84989181088     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/s13053-014-0022-x     Document Type: Article

References (24)

1. Patten DK, SharifiLK, Fazel M. New approaches in the management of male breast cancer. Clin Breast Cancer. 2013;13:309-14.
2. Haiminen N, Mannila H. Evaluation of BIC and cross validation for model selection on sequence segmentations. Int J Data Min Bioinform. 2010;4:675-700.
3. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:20-6.
4. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114-22.
5. Ly D, Forman D, Ferlay J, Brinton LA, Cook MB. An international comparison of male and female breast cancer incidence rates. Int J Cancer. 2014;132:1918-26.
6. Deb S, Jene N, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer. 2012;12:510.
7. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51-7.
8. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232-9.
9. Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol. 2013;717:71-83.
10. Thuler LCS, Bergmann A. Male breast cancer: clinical-epidemiological characteristics of 1189 Brazilian patients. Aging Male. 2014;5538:1-6.
11. Colombo-Benkmann M, Stern J, Herfarth C. On the neglected entity of unilateral gynecomastia. Ann Plast Surg. 2006;56:346.
12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
13. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108:18032-7.
14. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010;107:12629-33.
15. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, et al. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014;120:1557-64.
16. Gunhan-Bilgen I, Bozkaya H, Ustun E, Memis A. Male breast disease: clinical, mammographic, and ultrasonographic features. Eur J Radiol. 2002;43:246-55.
17. Onami S, Ozaki M, Mortimer JE, Pal SK. Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas. 2010;65:308-14.
18. Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998;58:1367-71.
19. Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmundsdottir HM, Tulinius H, et al. Linkage to BRCA2 region in hereditary male breast cancer. Lancet. 1995;346:544-5.
20. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13:123-5.
21. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60:1079-84.
22. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000;92:1126-35.
23. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22:735-42.
24. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-275.